CFTR | Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CHRM1 | Cholinergic receptor, muscarinic 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CHRM2 | Cholinergic receptor, muscarinic 2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CHRM3 | Cholinergic receptor, muscarinic 3 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
CHRM4 | Cholinergic receptor, muscarinic 4 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CHRM5 | Cholinergic receptor, muscarinic 5 | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
CHRNA3 | Cholinergic receptor, nicotinic, alpha 3 (neuronal) | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CHRNA4 | Cholinergic receptor, nicotinic, alpha 4 (neuronal) | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CHRNA7 | Cholinergic receptor, nicotinic, alpha 7 (neuronal) | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
CLCN2 | Chloride channel, voltage-sensitive 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
CNR1 | Cannabinoid receptor 1 (brain) | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CNR2 | Cannabinoid receptor 2 (macrophage) | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
COMT | Catechol-O-methyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CSF2RA | Colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CSF2RB | Colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CSF3R | Colony stimulating factor 3 receptor (granulocyte) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CYP19A1 | Cytochrome P450, family 19, subfamily A, polypeptide 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CYSLTR1 | Cysteinyl leukotriene receptor 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Mixed |
CYSLTR2 | Cysteinyl leukotriene receptor 2 | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DRD1 | Dopamine receptor D1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
DRD2 | Dopamine receptor D2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
DRD5 | Dopamine receptor D5 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EDNRB | Endothelin receptor type B | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EGF | Epidermal growth factor | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Group enriched |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
EPHA2 | EPH receptor A2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ERBB4 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
FADS1 | Fatty acid desaturase 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FADS2 | Fatty acid desaturase 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FCER1A | Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Mixed |
FCER1G | Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
FCGR2A | Fc fragment of IgG, low affinity IIa, receptor (CD32) | CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
FCGR2B | Fc fragment of IgG, low affinity IIb, receptor (CD32) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
FCGR3A | Fc fragment of IgG, low affinity IIIa, receptor (CD16a) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
FGFR1 | Fibroblast growth factor receptor 1 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FKBP1A | FK506 binding protein 1A, 12kDa | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FLT1 | Fms-related tyrosine kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
FLT3 | Fms-related tyrosine kinase 3 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
FLT4 | Fms-related tyrosine kinase 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FOLH1 | Folate hydrolase (prostate-specific membrane antigen) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
FXYD2 | FXYD domain containing ion transport regulator 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GABBR1 | Gamma-aminobutyric acid (GABA) B receptor, 1 | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GABBR2 | Gamma-aminobutyric acid (GABA) B receptor, 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GABRA1 | Gamma-aminobutyric acid (GABA) A receptor, alpha 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |